1. Phylogeny  
Transforming growth factor‐β receptor type‐1 (TGFBR1), also known as ALK5 or SKR4, belongs to the TGF‐β superfamily of transmembrane serine/threonine kinase receptors that are evolutionarily conserved across all vertebrate species (bakkebø2012transforminggrowthfactor pages 15-19). TGFBR1 is phylogenetically related to other type I receptors such as ALK4 and ALK7, which together form a subgroup specialized in transducing signals from TGF‐β and activin ligands (hilden2002expressionandregulation pages 17-20). Comparative kinase analyses place TGFBR1 within the larger serine/threonine kinome, and its evolutionary conservation underscores its indispensable role in regulating cellular homeostasis and developmental processes (randall2003smadpartnerinteractionsand pages 39-44). Global kinome studies have suggested that receptors of this family diverged early in metazoan evolution, and TGFBR1 is part of a core set of kinases whose ancestors can be traced back to the earliest common metazoans (nickel2019specificationofbmp pages 25-26).

2. Reaction Catalyzed  
TGFBR1 functions as a transmembrane serine/threonine kinase that catalyzes the phosphorylation of substrate proteins via the transfer of a phosphate group from ATP to specific serine/threonine residues (hinck2011structuresoftgf&amp;#946; pages 2-4). Upon activation by ligand‐induced phosphorylation from the associated TGF‐β type II receptor, TGFBR1 phosphorylates receptor‐regulated Smads—primarily Smad2 and Smad3—thereby converting them into active signaling mediators that propagate the TGF‐β signal (bakkebø2012transforminggrowthfactor pages 19-24).

3. Cofactor Requirements  
The catalytic activity of TGFBR1 requires the presence of divalent metal ions, with Mg²⁺ serving as an essential cofactor that stabilizes ATP binding within the active site and facilitates phosphoryl transfer during the catalytic cycle (bakkebø2012transforminggrowthfactor pages 19-24).

4. Substrate Specificity  
TGFBR1 exhibits a high substrate specificity for receptor‐regulated Smads, preferentially phosphorylating Smad2 and Smad3 at designated serine residues within a conserved C‐terminal SSXS motif (bakkebø2012transforminggrowthfactor pages 19-24). The enzyme’s recognition of its substrates is mediated by structural determinants within its kinase domain, including a specialized L45 loop that interacts with the corresponding L3 loop of the Smad MH2 domain, ensuring precise phosphorylation and subsequent downstream signal propagation (hinck2011structuresoftgf&amp;#946; pages 4-5).

5. Structure  
TGFBR1 is composed of three principal domains: an N‐terminal extracellular ligand‐binding domain, a single‐pass transmembrane helix, and a large intracellular serine/threonine kinase domain (hilden2002expressionandregulation pages 17-20). The extracellular domain, though relatively short compared to that of the type II receptor, contains seven conserved cysteine residues that form disulfide bonds and confer a stable structure required for ligand recognition (hilden2002expressionandregulation pages 12-15). Immediately following the transmembrane segment is a glycine/serine‐rich (GS) region that is indispensable for activation; this domain serves as the regulatory switch and is phosphorylated by the constitutively active type II receptor upon ligand binding (marcoux2005characterizationofa pages 22-27). The kinase domain itself is organized into 11 conserved subdomains typical of serine/threonine kinases and harbors key regulatory elements such as the activation loop and the L45 loop, which are critical for substrate engagement and specificity (hinck2011structuresoftgf&amp;#946; pages 17-18). In addition, structural studies have revealed that the cytoplasmic kinase domain of TGFBR1 can form complexes with regulatory proteins such as FKBP12, which binds to the GS domain in the receptor’s resting state and prevents untimely activation (hinck2011structuresoftgf&amp;#946; pages 1-2).

6. Regulation  
Regulation of TGFBR1 activity is achieved through a combination of ligand‐induced receptor complex formation, post‐translational modifications, and interactions with regulatory proteins. Ligand binding to TGF‐β receptor type II triggers the recruitment and transphosphorylation of TGFBR1’s GS domain, a critical step that dislodges the inhibitory protein FKBP12 and activates the kinase (bakkebø2012transforminggrowthfactor pages 19-24). Once activated, TGFBR1 phosphorylates receptor‐regulated Smads, a process that is tightly controlled by feedback inhibitors such as Smad7; Smad7 can bind directly to TGFBR1 to block access of R‐Smads and promote receptor ubiquitination via E3 ubiquitin ligases like Smurf1 and Smurf2, thereby targeting the receptor for degradation (bakkebø2012transforminggrowthfactor pages 24-28, randall2003smadpartnerinteractionsand pages 44-48). Furthermore, receptor internalization through clathrin‐mediated endocytosis and the involvement of adaptor proteins such as SARA modulate the intensity and duration of the TGF‐β signal by regulating the spatial and temporal dynamics of receptor–substrate interactions (wiercinska2005tgfβsmadsignaling pages 73-75).

7. Function  
TGFBR1 is central to the transduction of TGF‐β signals from the cell surface to the nucleus, thereby orchestrating a multitude of cellular processes. Upon formation of the heterotetrameric receptor complex with TGF‐β type II receptor and subsequent activation, TGFBR1 phosphorylates Smad2 and Smad3, which then dissociate, form complexes with Smad4, and translocate into the nucleus to modulate gene transcription (bakkebø2012transforminggrowthfactor pages 19-24, wiercinska2005tgfβsmadsignaling pages 73-75). The biological roles mediated by this signaling cascade include cell cycle arrest in epithelial and hematopoietic cells, regulation of mesenchymal cell proliferation and differentiation, and promotion of wound healing and extracellular matrix production (chua2024investigationonthe pages 22-27). Moreover, TGFBR1 is implicated in immunosuppressive responses and has been associated with carcinogenesis, acting as a key regulator in both tumor suppressive and tumor-promoting contexts depending on the cellular environment (bakkebø2012transforminggrowthfactor pages 74-82, chua2024investigationonthe pages 91-94).

8. Other Comments  
Small molecule inhibitors such as SB-431542 have been developed to specifically target the kinase activity of TGFBR1 and are widely used in experimental settings to modulate TGF‐β signaling (levesque2007transforminggrowthfactor pages 13-13). Therapeutic intervention strategies aimed at TGFBR1 are under active investigation in pathological conditions characterized by aberrant TGF‐β activity, including fibrotic disorders, various cancers (notably B-cell lymphoma), and certain neurodegenerative diseases (bakkebø2012transforminggrowthfactor pages 74-82, chua2024investigationonthe pages 91-94). In addition, dysregulation of receptor endocytosis and negative feedback via inhibitory Smads represents further avenues for therapeutic modulation, underscoring the multifaceted regulatory network that controls TGFBR1 signaling (randall2003smadpartnerinteractionsand pages 44-48).

References

1. (bakkebø2012transforminggrowthfactor pages 19-24): M Bakkebø. Transforming growth factor β superfamily signaling and its role in b-cell lymphoma. Unknown journal, 2012.

2. (chua2024investigationonthe pages 22-27): WH Chua. Investigation on the role of the transforming growth factor-beta pathway in a parkinson's disease cell model. Unknown journal, 2024.

3. (hilden2002expressionandregulation pages 17-20): K Hilden. Expression and regulation of human activins and their receptors. Unknown journal, 2002.

4. (hinck2011structuresoftgf&amp;#946; pages 17-18): Andrew P. Hinck and Maureen D. O'Connor-McCourt. Structures of tgf-&amp;#946; receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098, Dec 2011. URL: https://doi.org/10.2174/138920111798808383, doi:10.2174/138920111798808383. This article has 26 citations and is from a peer-reviewed journal.

5. (hinck2011structuresoftgf&amp;#946; pages 2-4): Andrew P. Hinck and Maureen D. O'Connor-McCourt. Structures of tgf-&amp;#946; receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098, Dec 2011. URL: https://doi.org/10.2174/138920111798808383, doi:10.2174/138920111798808383. This article has 26 citations and is from a peer-reviewed journal.

6. (wiercinska2005tgfβsmadsignaling pages 73-75): E Wiercinska. Tgf-β, smad signaling in hepatic stellate cells and during liver fibrogenesis. Unknown journal, 2005.

7. (bakkebø2012transforminggrowthfactor pages 15-19): M Bakkebø. Transforming growth factor β superfamily signaling and its role in b-cell lymphoma. Unknown journal, 2012.

8. (bakkebø2012transforminggrowthfactor pages 24-28): M Bakkebø. Transforming growth factor β superfamily signaling and its role in b-cell lymphoma. Unknown journal, 2012.

9. (bakkebø2012transforminggrowthfactor pages 74-82): M Bakkebø. Transforming growth factor β superfamily signaling and its role in b-cell lymphoma. Unknown journal, 2012.

10. (chua2024investigationonthe pages 91-94): WH Chua. Investigation on the role of the transforming growth factor-beta pathway in a parkinson's disease cell model. Unknown journal, 2024.

11. (hinck2011structuresoftgf&amp;#946; pages 1-2): Andrew P. Hinck and Maureen D. O'Connor-McCourt. Structures of tgf-&amp;#946; receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098, Dec 2011. URL: https://doi.org/10.2174/138920111798808383, doi:10.2174/138920111798808383. This article has 26 citations and is from a peer-reviewed journal.

12. (hinck2011structuresoftgf&amp;#946; pages 4-5): Andrew P. Hinck and Maureen D. O'Connor-McCourt. Structures of tgf-&amp;#946; receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098, Dec 2011. URL: https://doi.org/10.2174/138920111798808383, doi:10.2174/138920111798808383. This article has 26 citations and is from a peer-reviewed journal.

13. (levesque2007transforminggrowthfactor pages 13-13): Mathieu Lévesque, Samuel Gatien, Kenneth Finnson, Sophie Desmeules, Éric Villiard, Mireille Pilote, Anie Philip, and Stéphane Roy. Transforming growth factor: β signaling is essential for limb regeneration in axolotls. PLoS ONE, 2:e1227, Nov 2007. URL: https://doi.org/10.1371/journal.pone.0001227, doi:10.1371/journal.pone.0001227. This article has 164 citations and is from a peer-reviewed journal.

14. (marcoux2005characterizationofa pages 22-27): A Marcoux. Characterization of a novel tgf- accessory receptor in human keratinocytes. Unknown journal, 2005.

15. (nickel2019specificationofbmp pages 25-26): Joachim Nickel and Thomas D. Mueller. Specification of bmp signaling. Cells, 8:1579, Dec 2019. URL: https://doi.org/10.3390/cells8121579, doi:10.3390/cells8121579. This article has 137 citations and is from a peer-reviewed journal.

16. (randall2003smadpartnerinteractionsand pages 39-44): RA Randall. Smad-partner interactions and their roles in signalling by tgf- superfamily members. Unknown journal, 2003.

17. (randall2003smadpartnerinteractionsand pages 44-48): RA Randall. Smad-partner interactions and their roles in signalling by tgf- superfamily members. Unknown journal, 2003.

18. (hilden2002expressionandregulation pages 12-15): K Hilden. Expression and regulation of human activins and their receptors. Unknown journal, 2002.